CA2336134A1 - Use of texaphyrins in macrophage-mediated disease - Google Patents
Use of texaphyrins in macrophage-mediated disease Download PDFInfo
- Publication number
- CA2336134A1 CA2336134A1 CA002336134A CA2336134A CA2336134A1 CA 2336134 A1 CA2336134 A1 CA 2336134A1 CA 002336134 A CA002336134 A CA 002336134A CA 2336134 A CA2336134 A CA 2336134A CA 2336134 A1 CA2336134 A1 CA 2336134A1
- Authority
- CA
- Canada
- Prior art keywords
- texaphyrin
- macrophage
- disease
- therapeutic agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11050998A | 1998-07-06 | 1998-07-06 | |
US09/110,509 | 1998-07-06 | ||
PCT/US1999/015199 WO2000001414A1 (en) | 1998-07-06 | 1999-07-06 | Use of texaphyrins in macrophage-mediated disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2336134A1 true CA2336134A1 (en) | 2000-01-13 |
Family
ID=22333401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002336134A Abandoned CA2336134A1 (en) | 1998-07-06 | 1999-07-06 | Use of texaphyrins in macrophage-mediated disease |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1094840A1 (es) |
JP (1) | JP2002519390A (es) |
KR (1) | KR20010079498A (es) |
AR (1) | AR019226A1 (es) |
AU (1) | AU4860899A (es) |
CA (1) | CA2336134A1 (es) |
NO (1) | NO20010044L (es) |
WO (1) | WO2000001414A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6163988A (en) * | 1995-05-17 | 2000-12-26 | Rockland, Inc. | Assembly connectable to an operating arm of a machine for performing work functions |
RU2106146C1 (ru) | 1995-07-17 | 1998-03-10 | Институт элементоорганических соединений РАН | Средство для подавления опухолевого роста |
WO2001032210A2 (en) | 1999-10-29 | 2001-05-10 | Pharmacyclics, Inc. | Compositions for treating atheroma and neoplastic tissue |
US7579338B2 (en) | 1999-10-29 | 2009-08-25 | Pharmacyclics, Inc. | Methods and compositions for treating atheroma, tumors and other neoplastic tissues |
JP2003012547A (ja) * | 2001-06-27 | 2003-01-15 | Meiji Seika Kaisha Ltd | インスリン依存性糖尿病の診断剤および治療剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457183A (en) * | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
US5419760A (en) * | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US6008211A (en) * | 1995-07-27 | 1999-12-28 | Pdt Pharmaceuticals, Inc. | Photoactivatable compounds comprising benzochlorin and furocoumarin |
US5913884A (en) * | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
-
1999
- 1999-07-05 AR ARP990103250A patent/AR019226A1/es unknown
- 1999-07-06 WO PCT/US1999/015199 patent/WO2000001414A1/en not_active Application Discontinuation
- 1999-07-06 KR KR1020017000150A patent/KR20010079498A/ko not_active Application Discontinuation
- 1999-07-06 AU AU48608/99A patent/AU4860899A/en not_active Abandoned
- 1999-07-06 JP JP2000557860A patent/JP2002519390A/ja active Pending
- 1999-07-06 EP EP99932263A patent/EP1094840A1/en not_active Withdrawn
- 1999-07-06 CA CA002336134A patent/CA2336134A1/en not_active Abandoned
-
2001
- 2001-01-04 NO NO20010044A patent/NO20010044L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20010079498A (ko) | 2001-08-22 |
EP1094840A1 (en) | 2001-05-02 |
AU4860899A (en) | 2000-01-24 |
WO2000001414A1 (en) | 2000-01-13 |
AR019226A1 (es) | 2001-12-26 |
NO20010044D0 (no) | 2001-01-04 |
JP2002519390A (ja) | 2002-07-02 |
NO20010044L (no) | 2001-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2144327C (en) | Transcutaneous in vivo activation of photosensitive agents in blood | |
Zhou et al. | An ultrastructural comparative evaluation of tumors photosensitized by porphyrins administered in aqueous solution, bound to liposomes or to lipoproteins | |
JP2002534218A (ja) | 非侵襲性の脈管療法 | |
PL172480B1 (pl) | Kompozycja do niszczenia lub uszkadzania obszaru nowego unaczynienia PL PL | |
JP2002534219A (ja) | 標的細胞の経皮的な光力学的処置 | |
JP2003508124A (ja) | 長期間光活性化癌治療 | |
US4886831A (en) | Medical uses for phycocyanin | |
US20040171601A1 (en) | Photodynamic and sonodynamic therapy | |
Neave et al. | Hematoporphyrin uptake in atherosclerotic plaques: therapeutic potentials | |
Rovers et al. | Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra (hydroxyphenyl) chlorin (mTHPC), in a rat model | |
Ayaru et al. | Photodynamic therapy for pancreatic and biliary tract carcinoma | |
US5163898A (en) | Medical treatment of tumors with phycocyanin | |
Abels et al. | Targeting of the tumor microcirculation by photodynamic therapy with a synthetic porphycene | |
Veenhuizen et al. | Intraperitoneal photodynamic therapy in the rat: comparison of toxicity profiles for photofrin and MTHPC | |
Schaffer et al. | Porphyrins as radiosensitizing agents for solid neoplasms | |
Adili et al. | Photodynamic therapy with local photosensitizer delivery inhibits experimental intimal hyperplasia | |
Lin et al. | Photodynamic therapy of balloon-injured rat carotid arteries using indocyanine green | |
CA2336134A1 (en) | Use of texaphyrins in macrophage-mediated disease | |
US6495585B2 (en) | Method for treating hyperproliferative tissue in a mammal | |
US20020115649A1 (en) | Use of texaphyrins in macrophage-mediated disease | |
Osaki et al. | Efficacy of antivascular photodynamic therapy using benzoporphyrin derivative monoacid ring A (BPD-MA) in 14 dogs with oral and nasal tumors | |
Ma et al. | Enhanced antitumour effect of photodynamic therapy by microtubule inhibitors | |
Hsiang et al. | Determining the optimal dose of Photofrin® in miniswine atherosclerotic plaque | |
Nguyen et al. | Local drug delivery by fibrin glue for glioma treatment: Enhancing drug efficacy by photochemical internalization (PCI) | |
Andrejevic-Blant et al. | Interstitial photodynamic therapy with tetra (m-hydroxyphenyl) chlorin: tumor versus striated muscle damage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20050706 |